GenIP shares were higher on Tuesday after the AI analytics firm announced its entry into the UK academic market through two fresh engagements with UK-based research institutions.
The company, which provides generative AI services to help organisations commercialise innovations, signed deals with two universities following a month of industry networking and events across the UK. One institution is known for applied research and industry collaboration, whilst the other is recognised for its innovation pipeline across engineering, health sciences and digital technologies.
The breakthrough follows GenIP’s recent expansion into Chile and Brazil. GenIP said the UK contracts represent a significant milestone in the firm’s global growth strategy, establishing it as a trusted partner to leading research institutions.
GenIP has recently announced orders in excess of $850,000 since its IPO in late 2024. Today’s announcement will see this figure grow.
“Securing our first UK academic clients is a significant milestone for GenIP and a clear signal of growing demand for our AI-powered technology analytics platform. We’re proud to support leading research institutions that are actively investing in commercialising their innovation pipeline,” said Melissa Cruz, CEO of GenIP.
“These engagements come at a time of strong commercial momentum for GenIP. Following our participation in key industry events across the UK and Europe, we’ve experienced a material increase in inbound interest from both academic and corporate organisations. These new contracts and several other active commercial discussions underscore our traction in markets that value fast, scalable, and high-quality evaluation tools.
“GenIP is scaling rapidly, increasing adoption across universities, corporate R&D teams, and government innovation programmes. Our platform combines generative AI with expert analysis to help clients make faster, more informed decisions about which innovations to pursue.
“With a growing order book and a stable balance sheet heading into H2, we are focused on disciplined execution, expanding recurring revenues, and continuing to deliver long-term value to shareholders.”
GenIP shares were 2% higher at 35p at the time of writing.